SEATTLE, March 8, 2017 /PRNewswire/ -- CTI BioPharma
Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that
management will present at the 29th Annual ROTH
Conference on Tuesday, March 14,
2017, at 3:30 p.m.
PT/6:30 p.m. ET in
Dana Point, CA.
The presentation will be webcast live and available for replay
from the Investors section of CTI BioPharma's website at
www.ctibiopharma.com.
About CTI BioPharma
CTI BioPharma Corp. is a biopharmaceutical company focused on
the acquisition, development and commercialization of novel
targeted therapies covering a spectrum of blood-related cancers
that offer a unique benefit to patients and healthcare providers.
CTI BioPharma has a commercial presence in Europe with respect to PIXUVRI® and
a late-stage development pipeline, including pacritinib for the
treatment of patients with myelofibrosis. CTI BioPharma is
headquartered in Seattle,
Washington. For additional information and to sign up for
email alerts and get RSS feeds, please visit
www.ctibiopharma.com.
CTI BioPharma Contacts:
Ed Bell
+1 206-272-4345
ebell@ctibiopharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-29th-annual-roth-conference-300419763.html
SOURCE CTI BioPharma Corp.